Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today that the US Patent and Trademark Office has issued U.S. patent 8,822,218 covering methods of manufacturing dendritic cells using a highly scalable processing involving a readily renewable stem cell source as the starting materials. The derivation process covered by the patent provides a means for commercial scale manufacturing of an allogeneic, off-the-shelf immunotherapy platform.
http://ift.tt/1AeEyqo
http://ift.tt/1AeEyqo
No comments:
Post a Comment